Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| JBIO | PRESS-RELEASE | neutral | 3/10 | Jade Biosciences announced the first participant has been dosed in a Phase 1 clinical trial of JADE201, a half-life exte | May 26, 2026 |
| KLRA | PRESS-RELEASE | neutral | 4/10 | Kailera Therapeutics reported Q1 2026 net loss of $78.9M vs $18.0M in Q1 2025, with R&D expenses surging to $70.9M from | May 26, 2026 |
| APGE | PRESS-RELEASE | neutral | 6/10 | Apogee Therapeutics announced it will release Part B 16-week data from the Phase 2 APEX trial of zumilokibart on May 27, | May 26, 2026 |
| EDIT | PRESS-RELEASE | bearish | 8/10 | Editas Medicine priced a dilutive underwritten public offering of 55.6M shares and warrants at $2.25 per unit, raising ~ | May 26, 2026 |
| PRFX | PRESS-RELEASE | bullish | 5/10 | PRF Technologies announced positive preclinical head-to-head results for PRF-110 vs. ZYNRELEF in a pig incisional pain m | May 26, 2026 |
| RNXT | PRESS-RELEASE | bullish | 5/10 | RenovoRx announced the publication of a PK/PD sub-study from its Phase III TIGeR-PaC trial at ASCO 2026, showing that in | May 26, 2026 |
| SLXN | PRESS-RELEASE | bearish | 7/10 | Silexion Therapeutics announced a 1-for-10 reverse share split effective May 28, 2026, to regain compliance with Nasdaq' | May 26, 2026 |
| CMND | PRESS-RELEASE | neutral | 4/10 | Clearmind Medicine announced that the Johns Hopkins Medicine IRB has approved its Phase I/II trial of CMND-100 for Alcoh | May 26, 2026 |
| SXTP | PRESS-RELEASE | neutral | 4/10 | 60 Degrees Pharmaceuticals announced enrollment of the first patient of the 2026 tick season in a Phase 2 clinical trial | May 26, 2026 |
| CLDI | PRESS-RELEASE | neutral | 4/10 | Calidi Biotherapeutics announced that two abstracts on its RedTail platform (CLD-401 and CLD-501) were accepted for publ | May 26, 2026 |
| RYTM | PRESS-RELEASE | neutral | 2/10 | Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthc | May 26, 2026 |
| ESPR | PRESS-RELEASE | neutral | 5/10 | Esperion presented Phase 2 pediatric data and a CLEAR Outcomes post-hoc analysis at EAS 2026, showing bempedoic acid red | May 26, 2026 |
| QUCY | PRESS-RELEASE | bullish | 7/10 | Quantum Cyber announced that all outstanding warrants have been fully exercised, generating over $15 million in gross pr | May 26, 2026 |
| BCTXL | PRESS-RELEASE | neutral | 6/10 | BriaCell (BCTXL) received a sixth consecutive positive recommendation from the independent DSMB to continue its pivotal | May 26, 2026 |
| OTLK | PRESS-RELEASE | bullish | 8/10 | Outlook Therapeutics announced that the FDA granted its Formal Dispute Resolution appeal, concluding that substantial ev | May 26, 2026 |
| OLMA | PRESS-RELEASE | neutral | 4/10 | Olema Oncology announced a clinical trial collaboration with Bayer to evaluate its KAT6 inhibitor OP-3136 in combination | May 26, 2026 |
| RNAC | PRESS-RELEASE | bullish | 7/10 | Cartesian Therapeutics secured a $150M non-dilutive credit facility from K2 HealthVentures, with an initial $50M tranche | May 26, 2026 |
| EDIT | PRESS-RELEASE | bearish | 6/10 | Editas Medicine announced an underwritten public offering of common stock (or pre-funded warrants) and accompanying warr | May 26, 2026 |
| KURA | PRESS-RELEASE | bullish | 7/10 | Kura Oncology reported positive first-in-human Phase 1a data for darlifarnib plus adagrasib in KRAS G12C-mutated solid t | May 26, 2026 |
| EDIT | PRESS-RELEASE | bullish | 7/10 | Editas Medicine presented preclinical data for EDIT-401 at the EAS Congress, showing a single dose achieved ~90% mean re | May 26, 2026 |
| CLDI | PRESS-RELEASE | bearish | 7/10 | Calidi Biotherapeutics disclosed an audit report with a going-concern emphasis in its 2025 Form 10-K, required by NYSE A | May 22, 2026 |
| IOVA | PRESS-RELEASE | neutral | 2/10 | Iovance Biotherapeutics granted inducement stock options covering 93,340 shares to 13 new non-executive employees under | May 22, 2026 |
| GLSI | PRESS-RELEASE | bearish | 6/10 | Greenwich LifeSciences reported Q3 2025 EPS of -$0.30, beating consensus of -$0.32 by 6.3%, but the press release primar | May 22, 2026 |
| NBTX | PRESS-RELEASE | mixed | 6/10 | Nanobiotix closed its $100M global offering after underwriters fully exercised their option for 33,805 additional ADSs a | May 22, 2026 |
| ABVX | PRESS-RELEASE | neutral | 5/10 | Abivax reported Q1 2026 net loss of €48.5M (vs €52.4M loss in Q1 2025) with operating loss of €56.2M. The press release | May 22, 2026 |
| ONCY | PRESS-RELEASE | neutral | 4/10 | Oncolytics Biotech announced translational data from the GOBLET and AWARE-1 trials will be presented at ASCO 2026, showi | May 22, 2026 |
| AVXL | PRESS-RELEASE | bearish | 7/10 | Anavex Life Sciences disclosed a Nasdaq delinquency notice for failing to timely file its Q2 FY2026 Form 10-Q, adding to | May 22, 2026 |
| BCTXL | PRESS-RELEASE | bullish | 7/10 | BriaCell announced positive Phase 2 survival data for Bria-IMT in heavily pre-treated metastatic breast cancer, with med | May 22, 2026 |
| ASMB | PRESS-RELEASE | neutral | 5/10 | Assembly Bio is expanding ABI-6250, an oral NTCP inhibitor in Phase 1a for HDV, into cholestatic liver diseases (PBC/PSC | May 22, 2026 |
| ACIU | PRESS-RELEASE | bullish | 6/10 | AC Immune presented Phase 1 data at the 2026 TDP43 Summit showing its TDP-43 PET tracer ACI-19626 detects higher uptake | May 22, 2026 |